预约演示

NICE recommends Accord’s oral hormone therapy Orgovyx for advanced prostate cancer

2024-07-19

上市批准

The National Institute for Health and Care Excellence (NICE) has recommended Accord’s oral hormone therapy, Orgovyx (relugolix), for use in advanced prostate cancer patients.

The National Institute for Health and Care Excellence (NICE)fically recommendAccord those with hormone-sensiOrgovyxserelugolixdisease, is noadvanced prostate cancernt of its kind to be approved by the agency.

Prostate cancer is the most common cancer in men in the UK, with approximately 51,000 new cases diagnosed in England in 2022 alone.

Prostate cancerducing the level of canceren hormones, such as testosterone, which are needed by prostate cancer cells to grow.

Orgovyx reduces levels of testosterone by blocking the producttestosteroneormone in the testes aprostate cancera tablet, offering an alternative to other hormone treatments given by injection and providing patients with the option to take it at home.

Orgovyxfinal draft guidanctestosteroneg was supported by clinical trial evidence suggesting that Orgovyx is better at reducing testosterone to levels that stop cancer growth in the longer term than leuprolide and reduces the risk of serious cardiovascular events compared to leuprolide.

An indirect treatment comparison also demonstrated that Orgovyx works as well as other ADTs, the Orgovyxoutlined.cancer leuprolide leuprolide

Helen Knight, director of medicines evaluation at NICE, OrgovyxWe are continuing to focus on what matters most to people by recommending this innovative and effective treatment that can make a positive difference to people with advanced prostate cancer.

“[Orgovyx] provides a convenient and flexible treatment option compared with therapies that need to be injected, helping people to avoid travel and time off work and the evidence shows it can improve people’s quality of life.”advanced prostate cancer

ThOrgovyxmendation comes just one month after a mid-stage trial led by researchers from the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research found that hormone therapy in combination with radiotherapy could delay the need for chemotherapy in advanced prostate cancer patients.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构